VitalAire leads a panel discussion on the improvement of efficiency in household in Neumomadrid respiratory therapy
Madrid, may 2012.- on 20 April took place within the framework of Neumomadrid the round table how to improve efficiency in home respiratory therapy ” organized by VitalAire in collaboration with Dr. José Miguel Rodriguez-Gonzalez Moro and moderated by José MarÃa PinoDoctor’s Hospital La Paz in Madrid, attended by more than 80 pulmonologists in the community of Madrid to listen to speakers from various autonomous communities.
As conclusion we can highlight that two fundamental factors that all rapporteurs were included in his exhibition stand out in the field of efficiency in respiratory therapies: the proper prescription and adherence to treatment.
Pulmonologists specializing in home respiratory therapies as Dr. José Miguel RodrÃguez González-Moro of the Hospital Universitario Gregorio Marañón of Madrid, the Dr. Fernando mass Jiménez of the Hospital San Pedro de Alcántara in Cáceres, the Dr. Miguel Ãngel MartÃnez of the Hospital La Fe of Valencia and the Dr. Pere Casán of the Hospital Central de Asturias participated in this table of Oviedo. In addition, D. Francisco Crespo, Marketing Director, VitalAire intervened. In Spain, some 480,000 people suffer from some type of respiratory SHAS or COPD (chronic obstructive disease) among other pathology.
For its part, the Dr. José Miguel RodrÃguez González-Moro del Hospital Universitario Gregorio Marañón of Madrid stressed that these respiratory diseases affect 65,000 inhabitants and its interannual growth rate lies between 10 and 15% but there is underdiagnosis of 80%.
In this sense, the Dr. Fernando mass Jiménez of the Hospital San Pedro de Alcántara in Cáceres, explained the advantages of the respiratory & polygraphy to polysomnography to reduce Sleep Apnea (SAS) under-diagnosis. At this point he stressed that PR (respiratory & polygraphy) is less expensive, faster and allows to cover more people and discernió at what times it is more useful to use one against another, based on the prevalence of these diseases both with or without symptoms.
With regard to the adherence to the treatment, the Dr. Miguel Ãngel MartÃnez of the Hospital La Fe de Valencia, emphasized in his presentation on the causes that determine this adherence as environmental, technical and individual factors. This online pointed out that adherence in the first few days or weeks predicts long-term adherence, why a possibility to take into account is sedation for the patient to face with greater relaxation the first days of treatment. He stressed that collaborations as carried out with VitalAire in consultation point Orange ” Valencia are important for the achievement of the objectives of efficiency.
With regard to the intervention of the Dr. Pere Casán of the Hospital Central de Asturias of Oviedo, it highlighted the importance of improving the control of persons with respiratory treatments to reduce, as far as possible, the costs that these pathologies loaded to the system. In addition, claimed that the pulmonologist must be whoever does the prescription of oxygen provided that it is to be used long term.
Last spoke D. Francisco Crespo, Director of Marketing of VitalAire who presented the new model of management carried out by the company. As an example he mentioned the query point Orange opened last month in Valencia, which is located near the most important hospitals of the city. This is done for every patient prescribed a protocol with pedagogical and motivational support to the implementation and follow-up of the treatment of the prescription. addition, noted that patients with respiratory diseases not treaties pose one greater cost than those with treatment.
Piety Navarro, commercial Director of institutional relations of VitalAire, explaining that: there is a diversity of experiences by the Pulmonologists and different models in autonomous communities such as Madrid, Extremadura, Asturias and Valencia and, thanks to the close collaboration between the Pulmonologists and VitalAire, we can have an overview of the current situation that will allow us to establish one model efficient respiratory therapies. ”
Air Liquide is the world leader in gases for industry, health and the environment and is present in 80 countries with 46.200 collaborators. Oxygen, nitrogen, hydrogen and the noble gases are at the heart of the activity of Air Liquide since its creation in 1902. From these molecules Air Liquide continuously reinvents its business to anticipate the challenges of their present and future markets. The Group innovates to enable progress, at the time that excels in getting together a dynamic growth and regularity in their results.
Innovative technologies to limit emissions, reduce energy consumption of industry, put in value natural resources or develop the energies of tomorrow, such as hydrogen, biofuels or photovoltaic energy … oxygen for hospitals, home care, contribute to the fight against nosocomial diseases … Air Liquide combines many products with various technologies to develop applications and services with strong added value for its customers and society.
A partner for the long term. The Group relies on the commitment of its employees, the confidence of its customers and the support of its shareholders to develop a long-term focus on competitive growth vision. The diversity of its teams, activities, markets and geographical presence ensures the soundness and sustainability of their development, and strengthens its ability to continuously conquer new territories to overcome its own limits, and build their future.
Air Liquide explores the best that air can offer to preserve life, maintain a dynamic of responsibility and of sustainable development. In 2011, its turnover reached 14,500 million EUR of which more than 80% out of France. Air Liquide is listed on the stock exchange of Euronext Paris (compartment A) and is part of the CAC index 40 et Dow Jones Euro Stoxx 50.
